DOI: 10.1055/s-00000142

Frauenheilkunde up2date



Finn R.
Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Publication Number S1-6 2012 San Antonio Breast Cancer Symposium (SABCS).

Texas: San Antonio; 2012

Bibliographische Angaben herunterladen